哌拉西林/他唑巴坦用于危重症肥胖患者：病例系列：首例单中心治疗药物监测经验
Piperacillin/Tazobactam in critically ill morbidly obese patients: A case series: The first One-Centre experience with TDM.
作者信息
Mieresova M, Balazova K, Kubele J, Cerny D, Halacova M
机构信息
Department of Clinical Pharmacy Na Homolce Hospital Prague Czech Republic.
Department of Pharmacology Motol University Hospital and 2nd Faculty of Medicine, Charles University Prague Czech Republic.
出版信息
Clin Case Rep. 2023 Mar 11;11(3):e7032. doi: 10.1002/ccr3.7032. eCollection 2023 Mar.
Abstract
The aim of this article is to demonstrate extreme interindividual variability of piperacilin/tazobactam (PIP/TAZO) pharmacokinetics in critically ill morbidly obese patients and to emphasize the need for the practice of routine PIP/TAZO plasma concentrations measurement in order to ensure optimal efficacy and safety of antibiotic therapy.
摘要
本文旨在证明哌拉西林/他唑巴坦（PIP/TAZO）在危重症病态肥胖患者中的药代动力学存在极大的个体间差异，并强调需要常规测量PIP/TAZO血浆浓度，以确保抗生素治疗的最佳疗效和安全性。
相似文献
1
Piperacillin/Tazobactam in critically ill morbidly obese patients: A case series: The first One-Centre experience with TDM.哌拉西林/他唑巴坦用于危重症肥胖患者：病例系列：首例单中心治疗药物监测经验
Clin Case Rep. 2023 Mar 11;11(3):e7032. doi: 10.1002/ccr3.7032. eCollection 2023 Mar.
2
Pharmacokinetics of piperacillin and tazobactam in critically Ill patients treated with continuous kidney replacement therapy: A mini-review and population pharmacokinetic analysis.哌拉西林他唑巴坦在接受连续肾脏替代治疗的危重症患者中的药代动力学：迷你综述和群体药代动力学分析。
J Clin Pharm Ther. 2022 Aug;47(8):1091-1102. doi: 10.1111/jcpt.13657. Epub 2022 Mar 29.
3
Comparison of Piperacillin and Tazobactam Pharmacokinetics in Critically Ill Patients with Trauma or with Burn.哌拉西林和他唑巴坦在创伤或烧伤重症患者中的药代动力学比较
Antibiotics (Basel). 2022 May 4;11(5):618. doi: 10.3390/antibiotics11050618.
4
Piperacillin/tazobactam monotherapy versus piperacillin/tazobactam plus amikacin as initial empirical therapy for febrile neutropenia in children with acute leukemia.哌拉西林/他唑巴坦单药治疗与哌拉西林/他唑巴坦联合阿米卡星作为急性白血病患儿发热性中性粒细胞减少症初始经验性治疗的比较
Pediatr Hematol Oncol. 2011 May;28(4):311-20. doi: 10.3109/08880018.2011.557144.
5
Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients.哌拉西林在非肥胖、肥胖和病态肥胖重症患者中的群体药代动力学
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.01276-16. Print 2017 Mar.
6
Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience.治疗药物监测指导下哌拉西林/他唑巴坦持续输注显著提高危重症患者的药代动力学目标达标率：四年临床经验的回顾性分析。
Infection. 2019 Dec;47(6):1001-1011. doi: 10.1007/s15010-019-01352-z. Epub 2019 Aug 31.
7
Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections.静脉注射/口服环丙沙星联合甲硝唑与哌拉西林/他唑巴坦治疗复杂性腹腔内感染的比较
Ann Surg. 2000 Aug;232(2):254-62. doi: 10.1097/00000658-200008000-00016.
8
Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital.哌拉西林/他唑巴坦与亚胺培南/西司他丁治疗严重糖尿病足感染：大学医院的一项前瞻性、随机临床试验。
Clin Microbiol Infect. 2010 Aug;16(8):1252-7. doi: 10.1111/j.1469-0691.2009.03067.x. Epub 2009 Oct 14.
9
Experience with the use of piperacillin-tazobactam in pediatric non-renal solid organ transplantation.哌拉西林-他唑巴坦在小儿非肾实体器官移植中的应用经验。
Pediatr Transplant. 2007 Feb;11(1):38-48. doi: 10.1111/j.1399-3046.2006.00605.x.
10
Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients.哌拉西林他唑巴坦在危重症肥胖外科患者中的药代动力学分析。
Pharmacotherapy. 2014 Jan;34(1):28-35. doi: 10.1002/phar.1324. Epub 2013 Jul 17.
本文引用的文献
1
Pharmacokinetic aspects of beta-lactam antibiotic therapy in intensive care unit patients: A one-center experience with TDM.重症监护病房患者β-内酰胺类抗生素治疗的药代动力学研究：单中心治疗药物监测经验
Ceska Slov Farm. 2020 Winter;69(1):17-23.
2
Comprehensive Guidance for Antibiotic Dosing in Obese Adults.肥胖成人抗菌药物剂量调整的综合指导
Pharmacotherapy. 2017 Nov;37(11):1415-1431. doi: 10.1002/phar.2023. Epub 2017 Oct 30.
3
[Therapeutic drug monitoring of beta-lactam antibiotics].β-内酰胺类抗生素的治疗药物监测
Klin Mikrobiol Infekc Lek. 2017 Mar;23(1):4-9.
4
Repeated Piperacillin-Tazobactam Plasma Concentration Measurements in Severely Obese Versus Nonobese Critically Ill Septic Patients and the Risk of Under- and Overdosing.严重肥胖与非肥胖重症感染性患者哌拉西林-他唑巴坦血浆浓度的重复测量及用药不足和过量风险
Crit Care Med. 2017 May;45(5):e470-e478. doi: 10.1097/CCM.0000000000002287.
5
Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients.哌拉西林他唑巴坦在危重症肥胖外科患者中的药代动力学分析。
Pharmacotherapy. 2014 Jan;34(1):28-35. doi: 10.1002/phar.1324. Epub 2013 Jul 17.
6
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012.拯救脓毒症运动：严重脓毒症和脓毒性休克管理国际指南，2012 年。
Intensive Care Med. 2013 Feb;39(2):165-228. doi: 10.1007/s00134-012-2769-8. Epub 2013 Jan 30.
7
β-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review.β-内酰胺类药物在危重症患者中的药代动力学和药效学及剂量优化策略：系统评价。
Clin Exp Pharmacol Physiol. 2012 Jun;39(6):489-96. doi: 10.1111/j.1440-1681.2012.05715.x.
8
Dosing of piperacillin/tazobactam in a morbidly obese patient.肥胖症患者哌拉西林/他唑巴坦的给药剂量
J Antimicrob Chemother. 2012 Mar;67(3):782-3. doi: 10.1093/jac/dkr503. Epub 2011 Nov 30.
9
Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams.危重症患者中的抗生素：β-内酰胺类药物药代动力学的系统评价。
Crit Care. 2011;15(5):R206. doi: 10.1186/cc10441. Epub 2011 Sep 13.
10
Therapeutic drug monitoring of antimicrobials.抗菌药物治疗药物监测。
Br J Clin Pharmacol. 2012 Jan;73(1):27-36. doi: 10.1111/j.1365-2125.2011.04080.x.
Zotero 插件